Endra Life Sciences Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Endra Life Sciences Inc's ROA in the second quarter of 2026?
Endra Life Sciences Inc recorded a cumulative net loss of $-6 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -57.44%.

However, within the Healthcare sector 792 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4529, from total ROA ranking in the first quarter of 2026 at 5235.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	182.88 %	8.44 %	-4.02 %	-76.56 %	-73.11 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-7	-7	-8	-9
Return On Assets (TTM)	-57.44 %	-80.98 %	-78.51 %	-86.64 %	-80.82 %
NDRA's Total Ranking	# 4529	# 5235	# 4663	# 4662	# 4671
Total Assets (TTM) in million	8	3	28	2	3
Seq. Total Assets Change	131 %	-87.66 %	1318.47 %	-30.04 %	-11.45 %
Seq. Net Income Change	-	-	-	-	-

NDRA's 5 Years Annual ROA >> Back to NDRA Management Effectiveness >> Compare NDRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 184
Sector	# 793
Overall	# 4330

Return On Assets Statistics
High	Average	Low
-38.78 %	-178.32 %	-456.67 %
(Sep 30 2021)		(Sep 30 2018)

Financial Statements
Endra Life Sciences Inc's Assets	$ 8 million	NDRA's Balance sheet
Endra Life Sciences Inc's Income	$ 0 million	Quarterly NDRA's Income Statement
NDRA's Income by Division		See NDRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	525.75 %	-34.08 %	-27.17 %	-27.97 %	42.96 %
Total Assets in million	28	4	7	9	13
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-7	-12	-10	-13	-11
Annual Return On Assets	-25.22 %	-258.47 %	-148.95 %	-142.11 %	-88.18 %

NDRA's 5 Years Annual ROA >> Back to NDRA Management Effectiveness >> Compare NDRA ROA to its Competitors

More Return On Assets Ratios
NDRA's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NDRA's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NDRA's Competitors
Subscribers only: Roa for Endra Life Sciences Inc's Suppliers
Subscribers only: Return On Assets for NDRA's Customers

You may also want to know
NDRA's Roi	NDRA's Inventory Turnover Ratio	NDRA's Growth Rates	NDRA's Dividend Comparisons
	NDRA's Profitability Ratios	NDRA's Asset Turnover Ratio	NDRA's Dividend Growth
NDRA's Roe	NDRA's Valuation Ratios	NDRA's Financial Strength Ratios	NDRA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-17T07:27:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.